New-onset autoimmune disease after COVID-19

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 8, 2024

Introduction Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may trigger autoimmune disease (AD) through initial innate immune activation with subsequent aberrations in adaptive cells leading to AD. While there are multiple reports of incident AD diagnosed after COVID-19, the risk context key circulating strains is unknown. Methods TriNetX, a global, federated, health research network providing access electronic medical records across 74 healthcare organizations, was utilized define an adult cohort between January 1, 2020, and March 3, 2023. Exposure defined as COVID-19 diagnosis (ICD-10 code or positive laboratory test). Age- sex-propensity score-matched controls never had diagnosed. Outcomes were assessed 1 month year index date. Patients prior within date excluded from primary analysis. Incidence ratios each assessed. Results A total 3,908,592 patients included. Of 24 assessed, adjusted for eight who higher compared those no COVID-19. Cutaneous vasculitis (adjusted hazard ratio (aHR): 1.82; 95% CI 1.55–2.13), polyarteritis nodosa (aHR: 1.76; 1.15–2.70), hypersensitivity angiitis 1.64; 1.12–2.38) highest ratios. Overall, psoriasis (0.15%), rheumatoid arthritis (0.14%), type diabetes (0.13%) incidence during study period, these, more likely The any lower if when Omicron variants predominant strains. antinuclear antibody predictive Discussion SARS-CoV-2 be potential some AD, but decrease time given apparent infection variants.

Language: Английский

---

Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national survey study

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Feb. 27, 2024

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been a major challenge worldwide for the past years with high morbidity and mortality rates. While vaccination was cornerstone to control spread, concerns regarding safety adverse events (AEs) have raised lately. A cross-sectional study conducted between January 1st 22nd, 2022, in six Arabic countries namely Saudi Arabia, Egypt, Syria, Libya, Iraq, Algeria. We utilized self-administered questionnaire validated which encompassed two main parts. first sociodemographic data while second about COVID-19 history, types, doses, experienced AEs. multistage sampling employed each country, involving random selection of three governorates from followed by one urban area rural governorate. included responses 1564 participants. most common AEs after doses were local (67.9% 46.6%, respectively) bone pain myalgia (37.6% 31.8%, respectively). After third dose, (45.7%) fever (32.4%). Johnson Johnson, Sputnik Light, Moderna vaccines showed highest frequency Factors associated dose an increase age (aOR 61–75 compared 12–18 group: 2.60, 95% CI: 1.59–4.25, p = 0.001) male gender (OR: 0.72, 0.63–0.82, < 0.001). cumulative post-vaccination reported Sinovac (16.1%), Sinopharm (15.8%), (14.9) vaccines. History pre-vaccination SARS-CoV-2 infection significantly increases risk first, second, booster 3.09, 1.9–5.07, 0.0001; OR: 2.56, 1.89–3.47, 2.94, 1.6–5.39, 0.0005 In conclusion, among our participants, especially Further extensive studies are needed generate more generalizable different

Language: Английский

---

Post-COVID-19 Syndrome is Rarely Associated with Damage of the Nervous System: Findings from a Prospective Observational Cohort Study in 171 Patients

Neurology and Therapy, Journal Year: 2022, Volume and Issue: 11(4), P. 1637 - 1657

Published: Aug. 26, 2022

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can affect multiple organs. Reports of persistent or newly emergent symptoms, including those related to the nervous system, have increased over course pandemic, leading introduction post-COVID-19 syndrome. However, this novel is still ill-defined and structured objectification complaints scarce. Therefore, we performed a prospective observational cohort study better define validate subjective neurological disturbances in patients with syndrome.A total 171 fulfilling WHO Delphi consensus criteria underwent comprehensive diagnostic work-up neurovascular, electrophysiological, blood analysis. In addition, magnetic resonance imaging (MRI) lumbar puncture were conducted subgroups patients. Furthermore, neuropsychological, psychosomatic, fatigue assessment.Patients predominantly female, middle-aged, had incurred mostly mild-to-moderate COVID-19. most frequent included fatigue, difficulties concentration, memory deficits. (85.8%), in-depth assessment yielded no pathological findings. 97.7% cases, either diagnosis other than post COVID-19 syndrome, likely preceding could be established. Sensory motor more often associated Previous psychiatric conditions identified as risk factor for developing We found high somatization scores our patient group that correlated cognitive deficits extent fatigue.Albeit frequently reported by patients, objectifiable affection system rare Instead, elevated levels point towards pathogenesis potentially involving psychosomatic factors. thorough important order not miss diseases post-COVID-19.

Language: Английский

---

Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection

Nature Cardiovascular Research, Journal Year: 2022, Volume and Issue: 1(12), P. 1187 - 1194

Published: Dec. 12, 2022

Language: Английский

---

Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review

Pathology - Research and Practice, Journal Year: 2022, Volume and Issue: 232, P. 153834 - 153834

Published: March 4, 2022

Language: Английский

---

New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review

Rheumatology International, Journal Year: 2022, Volume and Issue: 42(12), P. 2267 - 2276

Published: Aug. 8, 2022

Dermatomyositis is a rare, type I interferon-driven autoimmune disease, which can affect muscle, skin and internal organs (especially the pulmonary system). In 2021, we have noted an increase in new-onset dermatomyositis compared to years before SARS-CoV-2 pandemic our center. We present four cases of NXP2 and/or MDA5 positive shortly after infection or vaccination. Three occurred within days vaccination with Comirnaty one case infection. All patients required intensive immunosuppressive treatment. antibodies could be detected three were found two (one patient was for both antibodies). this case-based systematic review, further analyze discuss literature on associated dermatomyositis. literature, sixteen reports (with total seventeen patients) association identified. Ten seven vaccination-associated seen mRNA vaccines. The reported included instance MDA5, NXP2, Mi-2 TIF1γ. reviewed suggest that may considered as potential trigger interferon-pathway. Consequently, might serve stimulus production dermatomyositis-specific autoantibodies like are closely related viral defense RNA interaction supporting concept

Language: Английский

---

COVID-19 Vaccines and Autoimmune Hematologic Disorders

Vaccines, Journal Year: 2022, Volume and Issue: 10(6), P. 961 - 961

Published: June 16, 2022

Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, incidence these AEs extremely low, their evolution may lead life-threatening scenarios if treatment readily initiated. Hematologic have associated both mRNA adenoviral vector-based main reported entities secondary immune thrombocytopenia, thrombotic thrombocytopenic purpura, hemolytic anemia, Evans syndrome, newly described disorder, so-called vaccine-induced thrombocytopenia (VITT). hallmark VITT presence anti-platelet factor 4 autoantibodies able trigger platelet activation. Patients present develop thrombosis unusual locations such as cerebral beds. management does differ significantly from that disorders non-vaccine context, thus addressing autoantibody production bleeding/thromboembolic risk. This means clinicians must be aware distinctive signs order diagnose them initiate soon possible.

Language: Английский

---

Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination

International Immunopharmacology, Journal Year: 2022, Volume and Issue: 110, P. 109061 - 109061

Published: July 15, 2022

Language: Английский

---

Understanding COVID-19 in children: immune determinants and post-infection conditions

Pediatric Research, Journal Year: 2023, Volume and Issue: 94(2), P. 434 - 442

Published: March 6, 2023

Language: Английский

---

An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 117, P. 109934 - 109934

Published: Feb. 27, 2023

Language: Английский

---